JNCCN 360 - Thyroid Cancer

Editor:

Robert I. Haddad, MD

Advertisement

Advertisement

Lori J. Wirth, MD, on RET-Altered Thyroid Cancer: Results From a Study on Selpercatinib

Enrique Grande, MD, PhD, on Targeted Treatment for Thyroid Cancer

Robert I. Haddad, MD, on Thyroid Cancer NCCN Clinical Practice Guidelines in Oncology®: Expert Perspective

Recent

Who May Benefit From Radioactive Iodine Ablation of Intermediate-Risk Papillary Thyroid Cancer?

COVID-19 and Thyroid Malignancies: Italian Researchers Focus on Quality of Life

Health-Related Quality of Life: RFA Versus Surgery for Papillary Thyroid Microcarcinoma

Management of Secondary Differentiated Thyroid Carcinoma in Childhood Cancer Survivors

Published

Medical Literature

Caveolin-1: Potential Biomarker of Papillary Thyroid Cancer?

Adding CT to Ultrasonography for Lymph Node Characterization in Thyroid Cancer

Is a Shift in Neutrophil-to-Lymphocyte Ratio Predictive of Outcomes in Anaplastic Thyroid Cancer?

Novel Combined-Modality Treatment of Locally Advanced Thyroid Cancer: Case Report

Ongoing

Differentiated thyroid cancer (DTC): therapeutic updates and optimizing treatment

A Unique Approach to Assessing the Risk of Indeterminate Thyroid Nodules

Current and Emerging Treatment Options for Lung Cancer and Head & Neck Carcinoma

Is Radioiodine Tx Overused in Low-Risk Thyroid Cancer?

Available

Clinical Trials

University of California, San Francisco

UT Southwestern Medical Center

Stanford Cancer Institute

UCLA/Jonsson Comprehensive Cancer Center

Advertisement

Advertisement

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.